Bevacizumab Against Recurrent Retinal Detachment

Retinal Detachment Clinical Trial

— BEARRD  

Official title:

Bevacizumab Against Recurrent Retinal Detachment

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02192970
• Other study ID #: 2014-0931
• Secondary ID: A536070SMPH/OPHT
• Status: Completed
• Phase: Phase 2
• Start date: January 21, 2015
• Est. completion date: November 11, 2019

Study information

• Verified date: March 2021
• Source: University of Wisconsin, Madison
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The investigators hypothesize that bevacizumab instilled into the vitreous after primary retinal detachment surgery will reduce the formation of proliferative vitreoretinopathy and subsequent retinal re-detachment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 101
• Est. completion date: November 11, 2019
• Est. primary completion date: November 11, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age = 18 years

• Eyes with rhegmatogenous retinal detachment

Exclusion Criteria:

• Presence of PVR

• Need for a procedure other than primary PPV such as a scleral buckle with or without PPV, laser retinopexy, or pneumatic retinopexy.

• Recent intravitreal injection of an anti-VEGF agent less than 3 months prior

• Secondary retinal detachment repair

• Use of silicone oil as tamponade agent

• Patients less than 18 years of age

• Pregnancy

• Known allergy or contraindication to intravitreal bevacizumab

Related Conditions & MeSH terms

• Dissociative Disorders
• Proliferative Vitreoretinopathy
• Retinal Detachment

Intervention

Drug:
• Bevacizumab

Locations

Country	Name	City	State
United States	University of Wisconsin	Madison	Wisconsin

Sponsors (1)

Lead Sponsor	Collaborator
University of Wisconsin, Madison

Country where clinical trial is conducted

United States, 

References & Publications (1)

Pennock S, Kim D, Mukai S, Kuhnle M, Chun DW, Matsubara J, Cui J, Ma P, Maberley D, Samad A, Van Geest RJ, Oberstein SL, Schlingemann RO, Kazlauskas A. Ranibizumab is a potential prophylaxis for proliferative vitreoretinopathy, a nonangiogenic blinding disease. Am J Pathol. 2013 May;182(5):1659-70. doi: 10.1016/j.ajpath.2013.01.052. Epub 2013 Apr 9. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants (or Chart Reviews) With Complete Success of Primary Vitrectomy Surgery	Complete success of primary vitrectomy surgery, defined as retinal re-attachment without the need for any additional surgical procedures.	6 months
Secondary	Number of Participants (or Chart Reviews) With Presence of Proliferative Vitreoretinopathy		6 months

External Links

•   Related Info